Antonio Buendia

Head of Manufacturing Process Controls
Antonio Buendia is Senior Principal Automation Engineer at NOVARTIS, responsible for the Automation of the 32 solids plants of Solids Platform. Previously, Antonio has worked for Elli Lilly in Madrid, where he shaped the site automation strategy and subsequent implementation driving productivity and quality. He has more than 20 years of experience in the areas of Industrial Automation, Operational technology, Project management, Facilities master planning, solid dosage, liquid dosage, R&D laboratories, and qualification of facilities, utilities and equipment. This wide experience in Engineering very close to Operations, allows him to link the technology dimension with the business needs. Antonio holds a Master for Industrial Engineering from the University of Comillas in Madrid. He is a founding member of the ISPE Spain, which chaired from 2007-2009 and as well as a member of the international board of Directors of the ISPE, Tampa from 2009-2011

Novartis Pharma AG

Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG.

Do NOT follow this link or you will be banned from the site!